Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/hepatitis C virus-coinfected patients treated for chronic hepatitis C.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Clinical Infectious Diseases

• Publication date

  2011-12-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/cid/cir665PMID 22028438
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR

  2011cited by this paper
• ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C

  2010cited by this paper
• Preemptive Erythropoietin Plus High Ribavirin Doses to Increase Rapid Virological Responses in HIV Patients Treated for Chronic Hepatitis C

  2010cited by this paper
• Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction.

  2010cited by this paper
• Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

  2009cited by this paper
• Role of Weight-Based Ribavirin Dosing and Extended Duration of Therapy in Chronic Hepatitis C in HIV-Infected Patients: The PRESCO Trial

  2007cited by this paper
• Modelling how ribavirin improves interferon response rates in hepatitis C virus infection

  2004cited by this paper
• Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C

  2004cited by this paper
• Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection

  2003cited by this paper
• Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

  2002cited by this paper
• Factors influencing ribavirin-induced hemolysis.

  2001cited by this paper
• Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group.

  1998cited by this paper
• For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group

  year unknowncited by this paper

• Pharmacogenetics and the treatment of HIV-/HCV-coinfected patients.

  2018cites this paper
• Impact of ITPA Gene Polymorphisms on the Risk of Ribavirin-Induced Haemolytic Anaemia using Interferon-Free Antivirals for Chronic Hepatitis C

  2017cites this paper
• Pharmacogenomic Testing in the Era of Patient-Tailored HCV Treatment

  2017cites this paper
• Is Ribavirin Teratogenic in Humans? No Evidence So Far

  2017cites this paper
• Pharmacogenetics of ribavirin-induced anemia in HCV patients.

  2016cites this paper
• Implications of Pharmacogenetics for Antimicrobial Prescribing

  2016cites this paper
• Estimated glomerular filtration rate but not solute carrier polymorphisms influences anemia in HIV–hepatitis C virus coinfected patients treated with boceprevir or telaprevir-based therapy

  2016cites this paper
• ITPA Deficiency and Ribavirin Level are Still Predictive of Anaemia in HCV–HIV-Coinfected Patients Receiving Ribavirin Combined with a First-Generation DAA (ANRS HC27 Study)

  2016cites this paper
• Relationship between ITPA polymorphisms and hemolytic anemia in HCV-infected patients after ribavirin-based therapy: a meta-analysis

  2015cites this paper
• Pharmacogenomics of antimicrobial agents.

  2014cites this paper
• The Role of Pharmacogenetics in the Treatment of Chronic Hepatitis C Infection

  2014cites this paper
• Distribution of genetic polymorphisms associated with hepatitis C virus (HCV) antiviral response in a multiethnic and admixed population

  2014cites this paper
• P9: Distribution of genetic polymorphisms associated to hepatitis C virus (HCV) antiviral response in a multiethnic and admixed population

  2013cites this paper
• Anemia Management in Patients with Chronic Viral Hepatitis C

  2013cites this paper
• Pharmacogenetics of Efficacy and Safety of HCV Treatment in HCV-HIV Coinfected Patients: Significant Associations with IL28B and SOCS3 Gene Variants

  2012cites this paper
• Management and Treatment of Chronic Hepatitis C in HIV Patients

  2012cites this paper
• Association of ITPA Gene Polymorphisms and the Risk of Ribavirin-Induced Anemia in HIV/Hepatitis C Virus (HCV)-Coinfected Patients Receiving HCV Combination Therapy

  2012cites this paper